Fertility tracking platform Inito has successfully raised $29 million in Series B funding to expand its at-home diagnostic capabilities and develop innovative AI-designed antibodies. The fresh capital will fuel the company’s evolution from a specialized fertility monitor into a comprehensive health diagnostics platform accessible from the comfort of home.
Revolutionizing Fertility Tracking with Comprehensive Hormone Analysis
When Inito introduced its fertility monitor in 2021, it addressed a significant gap in the market. Unlike conventional at-home ovulation tests that only track estrogen and Luteinizing Hormone (LH) to predict fertile days, Inito’s technology enables women to measure four critical hormones on a single test strip: estrogen, LH, progesterone metabolite (PdG), and Follicle Stimulating Hormone (FSH).
The inclusion of PdG measurement represents a substantial advancement, as it’s the only hormone that confirms actual ovulation rather than merely predicting it. This comprehensive approach provides women with significantly more accurate fertility insights than traditional methods. The platform’s sophisticated AI models analyze these hormone levels to identify fertility patterns, accurately track fertile windows, and confirm when ovulation has occurred.
Since its launch, Inito has processed over 30 million fertility hormone data points, establishing itself as a preferred solution for women seeking detailed reproductive health information without frequent lab visits. This extensive dataset not only validates the platform’s utility but also provides valuable information for continued refinement of its AI models.
The Game-Changing Potential of AI-Engineered Antibodies
A substantial portion of the new funding will be directed toward developing AI-engineered antibodies—a technological breakthrough that could fundamentally transform at-home testing capabilities. Traditional antibody development involves growing antibodies in animals followed by manual laboratory screening, a process that’s typically slow, expensive, and limited in sensitivity.
Inito’s co-founder and CTO, Varun A Venkatesan, explained their novel approach: